Vistin Pharma ASA
The answer first
Does Vistin Pharma beat the market?
No, Vistin Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 79% of Nordic stocks
- Quality92
- Value56
- Trend47
No. 27 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Vistin Pharma keeps shrinks about 3% a year for 10 years.
Max for seven days
Follow Vistin Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Vistin Pharma
Your first answer is free, no account needed.
Do you own Vistin Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Vistin Pharma and a few more. Free, no card.
Super Stock+44.6%In short
- Vistin Pharma has fallen 0.7% over the past year, including dividends.
- Overall, Vistin Pharma ranks better than 79% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 29.4%. The price is 24.5% below its peak now.
Who owns Vistin Pharma? See the major shareholders and their stakes
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 79% of Nordic stocks.
No. 27 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 30 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns1.02
- Return on equityProfit divided by equity+18.9%
- Cash conversionOperating cash flow divided by profit1.65
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 40 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.6
- P/SPrice divided by sales2.0
- P/EPrice divided by earnings13.5
- P/CFPrice divided by operating cash flow8.2
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 74 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−0.3%
- 6 months−9.6%
- 9 months−2.7%
- 12 months−0.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Vistin Pharma
Vistin Pharma ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 74 employees.
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.


See the full analysis of Vistin Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card